UY33334A - Proteina de fusion Robol-Fc y su utilizacion en el tratamiento de tumores . - Google Patents

Proteina de fusion Robol-Fc y su utilizacion en el tratamiento de tumores .

Info

Publication number
UY33334A
UY33334A UY0001033334A UY33334A UY33334A UY 33334 A UY33334 A UY 33334A UY 0001033334 A UY0001033334 A UY 0001033334A UY 33334 A UY33334 A UY 33334A UY 33334 A UY33334 A UY 33334A
Authority
UY
Uruguay
Prior art keywords
robol
tumors
treatment
fusion protein
protein
Prior art date
Application number
UY0001033334A
Other languages
English (en)
Inventor
Pierre Fons
Francis Blanche
Tarik Dabdoubi
Cameron Beatrice
Dol-Gleizes Frederique
Jean-Pascal Herault
Catherine Prades
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42830780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33334(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY33334A publication Critical patent/UY33334A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invencion se refiere a una proteina recombinante Robol-Fc y su utilizacion para tratar las enfermedades en las que se sobreexpresa una proteina Slit, en particular cancer. Se refiere igualmente a una composicion que comprende tal proteina recombinante . Otro aspecto de la invencion consiste en la utilizacion de una molecula Robol-Fc como herramienta de diagnostico para detectar la sobreexpresion de una molecula de la familia Slit en un paciente .
UY0001033334A 2010-04-14 2011-04-14 Proteina de fusion Robol-Fc y su utilizacion en el tratamiento de tumores . UY33334A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1052829A FR2958936A1 (fr) 2010-04-14 2010-04-14 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Publications (1)

Publication Number Publication Date
UY33334A true UY33334A (es) 2011-12-01

Family

ID=42830780

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033334A UY33334A (es) 2010-04-14 2011-04-14 Proteina de fusion Robol-Fc y su utilizacion en el tratamiento de tumores .

Country Status (26)

Country Link
US (1) US9493529B2 (es)
EP (1) EP2558489A1 (es)
JP (1) JP5858442B2 (es)
KR (1) KR20130059329A (es)
CN (1) CN102884076A (es)
AR (1) AR080891A1 (es)
AU (1) AU2011239839B2 (es)
BR (1) BR112012026020A2 (es)
CA (1) CA2796303A1 (es)
CL (1) CL2012002879A1 (es)
CR (1) CR20120508A (es)
DO (1) DOP2012000265A (es)
EA (1) EA201291044A1 (es)
EC (1) ECSP12012230A (es)
FR (1) FR2958936A1 (es)
GT (1) GT201200275A (es)
IL (1) IL222382A (es)
MA (1) MA34221B1 (es)
MX (1) MX338981B (es)
NI (1) NI201200155A (es)
PE (1) PE20130199A1 (es)
SG (1) SG184529A1 (es)
TN (1) TN2012000473A1 (es)
TW (1) TW201142024A (es)
UY (1) UY33334A (es)
WO (1) WO2011128561A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33833A (es) * 2010-12-23 2012-07-31 Sanofi Sa Proteína de fusión Robo1-Fc para su uso en el tratamiento del hepatocarcinoma
ES2714700T3 (es) 2012-01-05 2019-05-29 Boston Medical Ct Corp Señalización de SLIT-ROBO para el diagnóstico y el tratamiento de una enfermedad de riñón
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
CN109311949B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 储存分离基质的方法
WO2017194593A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
JP7018458B2 (ja) * 2017-06-02 2022-02-10 ファイザー・インク 組換えｒｏｂｏ２タンパク質、組成物、方法およびそれらの使用
EP3672992A4 (en) 2017-08-24 2021-05-19 Bar-Ilan University ROUNDABOUT FAMILY RECEPTOR INHIBITORS (ROBO) AND CORRESPONDING USES
US20220125879A1 (en) * 2019-02-27 2022-04-28 Daewoong Pharmaceutical Co., Ltd. Albumin-bound composition including lrrd2 of slit3 protein for prevention or treatment of bone-related diseases
CA3136663A1 (en) * 2019-04-23 2020-10-29 The Regents Of The University Of California Compositions and methods useful in promoting milk production

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
JP2003517262A (ja) * 1997-10-20 2003-05-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 神経誘導に含まれるポリペプチド及び核酸のファミリーであるｒｏｂｏ
JP2002510479A (ja) * 1998-04-02 2002-04-09 ライジェル・ファーマシューティカルズ・インコーポレイテッド コンパクトな構造の形成を引き起こすペプチド
AU2001283062A1 (en) * 2000-08-02 2002-02-13 The Johns Hopkins University Endothelial cell expression patterns
WO2003075860A2 (en) 2002-03-08 2003-09-18 Abgent, Inc. Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
EP2311468B1 (en) * 2003-08-08 2014-01-15 Perseus Proteomics Inc. Gene overexpressed in cancer
BRPI0507174A (pt) * 2004-01-28 2008-04-01 Syntonix Pharmaceuticals Inc proteìnas de fusão hormÈnio-fc (fsh-fc) heterodiméricas estimuladoras de folìculo para o tratamento da infertilidade
RU2466740C2 (ru) * 2006-04-05 2012-11-20 Эбботт Байотекнолоджи Лтд. Очистка антитела
CL2007003411A1 (es) 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
EP2599791A1 (en) * 2007-04-27 2013-06-05 Genentech, Inc. Potent, stable and non-immunosuppressive anti-CD4 antibodies
SG10201407388XA (en) 2007-08-29 2015-01-29 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof

Also Published As

Publication number Publication date
CL2012002879A1 (es) 2013-03-22
US9493529B2 (en) 2016-11-15
GT201200275A (es) 2014-01-24
BR112012026020A2 (pt) 2016-06-28
NI201200155A (es) 2013-02-05
IL222382A0 (en) 2012-12-31
WO2011128561A1 (fr) 2011-10-20
IL222382A (en) 2016-06-30
CN102884076A (zh) 2013-01-16
US20130039912A1 (en) 2013-02-14
FR2958936A1 (fr) 2011-10-21
PE20130199A1 (es) 2013-03-09
MX338981B (es) 2016-05-06
AR080891A1 (es) 2012-05-16
DOP2012000265A (es) 2013-02-28
KR20130059329A (ko) 2013-06-05
MX2012011822A (es) 2012-11-12
MA34221B1 (fr) 2013-05-02
ECSP12012230A (es) 2012-11-30
TW201142024A (en) 2011-12-01
CR20120508A (es) 2012-11-01
EA201291044A1 (ru) 2013-04-30
TN2012000473A1 (fr) 2014-01-30
JP2013523172A (ja) 2013-06-17
JP5858442B2 (ja) 2016-02-10
SG184529A1 (en) 2012-11-29
AU2011239839A1 (en) 2012-11-08
EP2558489A1 (fr) 2013-02-20
AU2011239839B2 (en) 2015-08-20
CA2796303A1 (fr) 2011-10-20

Similar Documents

Publication Publication Date Title
UY33334A (es) Proteina de fusion Robol-Fc y su utilizacion en el tratamiento de tumores .
PH12018500768A1 (en) Purin derivatives for use in the treatment of fab-related diseases
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
PA8819201A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
UY30663A1 (es) Dihidropirazolonas sustituidas y su uso
GT201200313A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
EA201290727A1 (ru) Пирролбензодиазепины и их конъюгаты
CR20110560A (es) Métodos de tratamiento para tumores sólidos
GB201209613D0 (en) New compounds
CR20110509A (es) Composicion farmaceutica
BR112012030479A2 (pt) terapia aprimorada de câncer baseada em antígenos associados a tumor derivados de ciclina d1
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
BR112013016107A2 (pt) molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar
EA201170190A1 (ru) Фармацевтическая композиция, содержащая экстракт мозга свиньи
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma
BR112015006363A2 (pt) combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
BR112013024265A2 (pt) peptídeo cíclico, uso de peptídeos cíclicos, método para o tratamento de doenças, composição farmacêutica, composto para o diagnóstico de câncer, e, combinação farmacêutica
CY1118402T1 (el) Η χρηση πηγης l3 και/ή l5 ως εμβολιου ή ως διαγνωστικου για παρασιτικη παθηση

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200623